Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DW4421 and Amoxicillin/Clarithromycin DDI Study
NCT07382661Phase 1Not yet recruiting
- Sponsor
- Daewon Pharm
- Start
- Feb 2026
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DW4421-1 in Helicobacter pylori infection, sponsored by Daewon Pharm. Primary endpoints: Maximum concentration at steady state at 7 days and Area under the drug concentration-time curve within a dosing interval at steady state at 7 days. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
DW4421-1
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT07382661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07382661.